Latest Conference Articles

Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

During an interview with Dermatology Times, Chovatiya outlined his Fall Clinical 2024 presentations on chronic hand eczema and early career controversies.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Del Rosso reviews available and upcoming monoclonal antibodies, including nemolizumab, lebrikizumab, bimekizumab, and more.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

Del Rosso reviews numerous new and upcoming topical therapeutics and indications including ruxolitinib, tapinarof, and more.

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The conference will feature presentations on a number of disease states, therapeutic options, and new clinical data.

Share with us the topics you want to learn more about at Fall Clinical.

Findings from 2 phase 3 trials indicate that ZORYVE cream significantly improves both clinical outcomes and quality of life in patients with mild to moderate atopic dermatitis.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

Whether you're a novice or a seasoned expert, there's always more to learn and refine, ensuring that dermatology continues to advance with precision and care.

Review insights from expert faculty as they look forward to the upcoming Elevate-Derm conference.

Experts shared pearls for acne and rosacea care at Maui Derm NP+PA Fall.

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.

A poster presented at the EADV Congress revealed the drug's long-term efficacy in treating AD, particularly in the head and neck regions.

Connect with peers, mentors, and potential collaborators at the fully accredited Elevate Derm PA NP Conference, from November 7-10, 2024.